No images for this product yet
Product Info Summary
| SKU: | P00029 |
|---|---|
| Size: | 100 μl/vial |
| Reactive Species: | Human, Mouse, Rat |
| Host: | Rabbit |
| Application: | WB |
Customers Who Bought This Also Bought
Product info
Product Name
Anti-Phospho-PI3 Kinase p110 Alpha/PIK3CA (Y317) Antibody
SKU/Catalog Number
P00029
Size
100 μl/vial
Form
Liquid
Description
Boster Bio Anti-Phospho-PI3 Kinase p110 Alpha/PIK3CA (Y317) Antibody catalog # P00029. Tested in WB applications. This antibody reacts with Human, Mouse, Rat.
Storage & Handling
12 months from date of receipt，-20℃ as supplied. 6 months 2 to 8℃ after reconstitution. Avoid repeated freezing and thawing.
Cite This Product
Anti-Phospho-PI3 Kinase p110 Alpha/PIK3CA (Y317) Antibody (Boster Biological Technology, Pleasanton CA, USA, Catalog # P00029)
Host
Rabbit
Contents
500 μg/ml antibody with PBS, 0.02% NaN3, 1 mg stabilizing protein and 50% glycerol
This antibody is supplied in a stabilized formulation.
Compatibility with conjugation reactions depends on the chemistry of the conjugation method used.
For conjugation methods that are not compatible with the stabilizing components present in this formulation, a carrier-free antibody format is required.
Clonality
Polyclonal
Immunogen
A synthesized peptide derived from human PIK3CA around the phosphorylation site of Tyr317.
Reactive Species
P00029 is reactive to PIK3CA in Human, Mouse, Rat
Calculated molecular weight
124.3 kDa
Background of PIK3CA
Phosphatidylinositol-4,5-bisphosphate 3-kinase, also called PIK3CA, is composed of an 85 kDa regulatory subunit and a 110 kDa catalytic subunit. PIK3CA gene is mapped to 3q26.32. The protein encoded by this gene represents the catalytic subunit, which uses ATP to phosphorylate phosphatidylinositols (PtdIns), PtdIns4P andPtdIns(4,5)P2. Recent evidence has shown that the PIK3CA gene is mutated in a range of human cancers. It has been found to be oncogenic and has been implicated in cervical cancers. PIK3CA mutations in breast cancer may be a predictive marker to guide the selection of patients who would benefit from mTOR inhibitor therapy. In addition to that, the presence of PIK3CA mutation may predict response to aspirin therapy for colorectal cancer, indicating power and promise of "Molecular Pathological Epidemiology (MPE)" approach as well as a complex interaction within the tumor microenvironment in this phenomenon.
Antibody Validation
Boster validates all antibodies on WB, IHC, ICC, Immunofluorescence, and ELISA with known positive control and negative samples to ensure specificity and high affinity, including thorough antibody incubations.
Application & Images
Applications
P00029 is guaranteed for WB Boster Guarantee
Assay Dilutions Recommendation
The recommendations below provide a starting point for assay optimization. The actual working concentration varies and should be decided by the user.
Western blot, 1:500-2000
Validation Images & Assay Conditions
There are currently no images for this product. We are working on uploading them please check back shortly or contact us to expedite our upload process for this antibody.
Specific Publications For Anti-Phospho-PI3 Kinase p110 Alpha/PIK3CA (Y317) Antibody (P00029)
Loading publications
Recommended Resources
Here are featured tools and databases that you might find useful.
- Boster's Pathways Library
- Protein Databases
- Bioscience Research Protocol Resources
- Data Processing & Analysis Software
- Photo Editing Software
- Scientific Literature Resources
- Research Paper Management Tools
- Molecular Biology Software
- Primer Design Tools
- Bioinformatics Tools
- Phylogenetic Tree Analysis
Customer Reviews
Have you used Anti-Phospho-PI3 Kinase p110 Alpha/PIK3CA (Y317) Antibody?
Share your experimental results or join a short interview to earn up to $1,000 in product credits or other rewards.
0 Reviews For Anti-Phospho-PI3 Kinase p110 Alpha/PIK3CA (Y317) Antibody
Customer Q&As
Have a question?
Find answers in Q&As, reviews.
Can't find your answer?
Submit your question
